Session Details
[C1]Corporate Exhibitions
Tue. Jul 7, 2026 2:10 PM - 3:10 PM JST
Tue. Jul 7, 2026 5:10 AM - 6:10 AM UTC
Tue. Jul 7, 2026 5:10 AM - 6:10 AM UTC
Corporate Exhibits( Ito International Research Center B2)
[C1-01]Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms
*Taro Saito1, Arnaud Couzinet2, Toshihiro Suzuki2, Kei Miyakawa3, Tetsuya Nakatsura2 (1. Canon Medical Diagnostics Corporation (Japan), 2. Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center (Japan), 3. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))
[C1-02]Analytical Performance and Inter-Laboratory Reproducibility of LeukoCompleteTM Assay
Taro Saito1, Oliver McKenzie2, Daniel J. Wilson2, Jalil Hakimi2, *Takaya Sato1 (1. Canon Medical Diagnostics Corporation (Japan), 2. Pegasus Biotech Inc. (Canada))
[C1-03]Exibition for Bioprocess support materials
*Natsumi Kimura1 (1. Merck Ltd. Process Solutions (Japan))
[C1-04]Introduction to Our Cell Culture Products and Contract Services
*Hiroyuki Hata1 (1. Kyokuto pharmaceutical industrial Co., Ltd. (Japan))
[C1-05]Support for the Development of Pharmaceuticals, Medical Devices, and Regenerative Medicine Products by the EPS Group
*Yasushi Ashikawa2, Yuta Okugi3, Saburo Niki1 (1. Sales Department, Sales Planning Promotion Center, EPS Corporation (Japan), 2. Government Affairs Business Planning Office, Comprehensive Planning Center, EPS Corporation (Japan), 3. Business Planning Promotion Office, Business Planning Promotion Center, Real World Evidence Business Division, EPS Corporation (Japan))
[C1-06]Company introduction
*Akihito Sawada1, Kazuyuki Ikeda1 (1. Meiji Seika Pharma Co., Ltd. (Japan))
[C1-07]Patents are the first step toward social implementation.
*Yoichi Maruyama1 (1. The UTOPIA Center, The University of Tokyo (Japan))